Volume 6.38 | Oct 9

Prostate Cell News 6.38 October 9, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PCN on Twitter
 
TOP STORY
Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation
Researchers showed that androgen receptor expression and activity are durably upregulated following radiotherapy in multiple human prostate cancer models in vitro and in vivo. [Cancer Res] Abstract
Cryopreservation Media for Stem Cells - Learn More!
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

MicroRNA-212 Negatively Regulates Starvation Induced Autophagy in Prostate Cancer Cells by Inhibiting SIRT1 and Is a Modulator of Angiogenesis and Cellular Senescence
Researchers demonstrated that microRNA (miR)-212 negatively modulates starvation induced autophagy in prostate cancer cells by targeting sirtuin 1 (SIRT1). Overexpression of miR-212 also leads to inhibition of angiogenesis and cellular senescence. [Oncotarget] Full Article

Co-Targeting Polo-Like Kinase 1 (Plk1) and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer
Scientists showed that Plk1 is a negative regulator of Wnt/β-catenin signaling. Plk1 inhibition or depletion enhances the level of cytosolic and nuclear β-catenin in human prostate cancer cells. [Mol Cell Biol] Abstract

Differential Redox Regulation of Ca2+ Signaling and Viability in Normal and Malignant Prostate Cells
Researchers investigated alterations of intracellular Ca2+ and inhibition of cell viability caused by reactive oxygen species in primary human prostate epithelial cells (hPECs) from healthy tissue and prostate cancer cell lines. In hPECs, LNCaP and DU145 H2O2 induces an initial Ca2+ increase, which in prostate cancer cells is blocked at high concentrations of H2O2. [Biophys J] Abstract

GSK-3β Controls Autophagy by Modulating LKB1-AMPK Pathway in Prostate Cancer Cells
Inhibition of glycogen synthase kinase 3β (GSK-3β) activity resulted in a significant decline of cellular ATP production, leading to a significant increase of AMP/ATP ratio, a strong trigger of AMP-activated protein kinase (AMPK) activation in prostate cancer PC-3 cells. [Prostate] Abstract

The Influence of Prostatic Anatomy and Neurotrophins on Basal Prostate Epithelial Progenitor Cells
The effect of neurotrophins NGF, NT3, and BDNF were evaluated with respect to their influence on proliferation and activation of human basal prostate epithelial progenitor cells in vitro. [Prostate] Abstract

Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth
Scientists examined the anti-cancer effect of Exendin–4 and metformin using a prostate cancer model. Exendin–4 and metformin additively decreased the growth curve, but not the migration, of prostate cancer cells. [PLoS One] Full Article

Anti-IL-20 Monoclonal Antibody Suppresses Prostate Cancer Growth and Bone Osteolysis in Murine Models
Researchers hypothesized that interleukin (IL)–20 promotes the growth of prostate cancer cells. In vitro, IL–20 upregulated N-cadherin, STAT3, vimentin, fibronectin, RANKL, cathepsin G, and cathepsin K, and increased the migration and colony formation of prostate cancer cells via activated p38, ERK1/2, AKT, and NF-κB signals in PC–3 cells. [PLoS One] Full Article

Antitumor Activity of Garcinol in Human Prostate Cancer Cells and Xenograft Mice
Garcinol, a polyisoprenylated benzophenone from fruits rinds of Garcinia indica, was studied for its antitumor activity by inducing apoptosis and inhibiting autophagy in human prostate cancer cells. The Bax/Bcl-2 ratio increased when garcinol was applied to PC-3 cells indicating a presence of apoptosis. [J Agric Food Chem] Abstract

CLINICAL RESEARCH

Haptoglobin Promoter Polymorphism rs5472 as a Prognostic Biomarker for Peptide Vaccine Efficacy in Castration-Resistant Prostate Cancer Patients
To detect a molecular prognosticator of clinical outcomes for personalized peptide vaccination (PPV), investigators analyzed whole-genome gene expression profiles of peripheral blood mononuclear cells in castration-resistant prostate cancer patients before administration of PPV. [Cancer Immunol Immunother] Abstract

[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
 
REVIEWS
MicroRNA in Prostate Cancer
The authors review the regulation of microRNAs (miRNAs) in prostate cancer and their mechanisms which contribute to prostate carcinogenesis. The relation of miRNAs with androgen signaling is highlighted and the prospects of miRNAs for clinical therapies are also discussed. [Clin Chim Acta] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
 
SCIENCE NEWS
Tokai Pharmaceuticals Announces Presentation of AR-V7 Clinical Trial Assay
Tokai Pharmaceuticals, Inc. announced that a detailed overview of its AR-V7 clinical trial assay will be presented at a poster session. The AR-V7 clinical trial assay reliably detected both full-length androgen receptor and the AR-V7 splice variant under a variety of conditions in AR-positive circulating tumor cells of men with treatment-naïve metastatic castration resistant prostate cancer. [Press release from Tokai Pharmaceuticals, Inc. discussing research presented at the 22nd Annual Prostate Cancer Foundation Scientific Retreat, Washington, DC] Press Release

From our sponsor:
Discover how to reduce variability in primary neuron cultures with NeuroCult™ SM.
Watch the webinar.
 
INDUSTRY NEWS
OncoGenex Announces EMA Support for Phase III AFFINITY Trial Protocol Amendment
OncoGenex Pharmaceuticals, Inc. announced that the European Medicines Agency (EMA) has completed its review of the proposed amendment to the company’s Phase III AFFINITY protocol and statistical analysis plan. [OncoGenex Pharmaceuticals, Inc.] Press Release

Oncolytics Biotech® Inc. Announces Completion of Enrollment in Randomized Phase II Prostate Cancer Study
Oncolytics Biotech® Inc. announced that enrollment has been completed in a randomized Phase II study of REOLYSIN® in patients with recurrent or metastatic castration resistant prostate cancer. [Oncolytics Biotech® Inc.] Press Release
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW European Society for Medical Oncology (ESMO) Asia 2015 Congress
December 18-21, 2015
Singapore, Singapore

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Position – Cancer Research (University of Texas Health Science Center at Houston)

NEW PhD Studentships – Cancer Research (Cancer Research UK Manchester Institute)

NEW Postdoctoral Associate – Bioinformatics (Baylor College of Medicine)

Clinical Research Fellow – Prostate Cancer Biology (Cancer Research UK Manchester Institute)

Staff Scientist – Prostate Cancer Modeling (Fred Hutchinson Cancer Research Center)

Research Scientist – Epithelial Stem Cells (A*STAR)

Postdoctoral Fellow – Prostate Cancer Research (Rutgers Cancer Institute of New Jersey)

Postdoctoral Researcher – Epigenetic Modifiers (Van Andel Research Institute)

Postdoctoral Positions – Stem Cell, Development and Cancer Biology (Columbia University Medical Center)

Staff Scientist – Cancer Modeling (Fred Hutchinson Cancer Research Center)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us